Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP11B2 | P19099 | 1/20 | 0.58 |
| ▸ | GRM1 | Q13255 | 9/20 | 0.50 |
| ▸ | GRM5 | P41594 | 9/20 | 0.50 |
| ▸ | NAMPT | P43490 | 1/20 | 0.48 |
| ▸ | TLR7 | Q9NYK1 | 1/20 | 0.48 |
| ▸ | PDK4 | Q16654 | 1/20 | 0.47 |
| ▸ | CDK7 | P50613 | 1/20 | 0.44 |
| ▸ | CDK13 | Q14004 | 1/20 | 0.44 |
| ▸ | CDK12 | Q9NYV4 | 1/20 | 0.44 |
| ▸ | QDPR | P09417 | 1/20 | 0.43 |
| ▸ | JAK1 | P23458 | 1/20 | 0.43 |
| ▸ | BTK | Q06187 | 1/20 | 0.43 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.42 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20753874 | 1.00 | CYP11B2 (0.58) | CYP11B2GRM1GRM5NAMPTTLR7 | |
| SCHEMBL23865569 | 0.88 | QDPR (0.46) | CYP11B2NAMPTQDPR | |
| SCHEMBL13473291 | 0.87 | CYP11B2 (0.61) | CYP11B2GRM1GRM5NAMPTTLR7 | |
| SCHEMBL30032127 | 0.85 | CYP11B2 (0.59) | CYP11B2GRM1GRM5NAMPTTLR7 | |
| SCHEMBL2883881 | 0.85 | CYP11B2 (0.59) | CYP11B2GRM1GRM5NAMPTTLR7 | |
| SCHEMBL4163933 | 0.85 | CYP11B2 (0.59) | CYP11B2GRM1GRM5NAMPTTLR7 | |
| SCHEMBL16271570 | 0.85 | CYP11B2 (0.61) | CYP11B2GRM1GRM5NAMPTTLR7 | |
| SCHEMBL30191814 | 0.85 | CYP11B2 (0.59) | CYP11B2GRM1GRM5NAMPTTLR7 | |
| SCHEMBL30305366 | 0.85 | CYP11B2 (0.61) | CYP11B2GRM1GRM5NAMPTTLR7 | |
| SCHEMBL22324984 | 0.84 | QDPR (0.47) | CYP11B2NAMPTQDPR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12479816-B2 | 20-HETE formation inhibitors | University of Pittsburgh—of the Commonwealth System of Higher Education (US) | 2025-11-25 | — | — | US | disclosed |
| CN-115279765-B | 1H-pyrazolo [4,3-d ] pyrimidine compounds as Toll-like receptor 7 (TLR 7) agonists | 百时美施贵宝公司 | 2024-11-12 | — | — | CN | disclosed |
| CN-115279765-A | 1H-pyrazolo [4,3-d ] pyrimidine compounds as Toll-like receptor 7 (TLR 7) agonists | 百时美施贵宝公司 | 2022-11-01 | — | — | CN | disclosed |
| US-20220144797-A1 | 20-HETE FORMATION INHIBITORS | UNIVERSITY OF PITTSBURGH - OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (US) | 2022-05-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220144797-A1 | 20-HETE FORMATION INHIBITORS | CYP4A22, ALOX5, ALOX15 | CYP11B2 7/4885GRM1 2182/4885GRM5 1092/4885 |
| US-12479816-B2 | 20-HETE formation inhibitors | CYP4A22, ALOX5, ALOX15 | CYP11B2 7/4885GRM1 2182/4885GRM5 1092/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.